While endocrine therapies are widely employed for treating HR+/HER2- breast cancer, many patients with advanced or metastatic disease eventually develop resistance. As the treatment landscape continues to evolve, it is important to stay up to date on key advancements in managing endocrine resistance in this setting. Tune in to hear expert faculty discuss: incorporating biomarker testing to guide treatment selection the latest clinical evidence for novel targeted therapies strategies for selecting optimal treatment plans based on biomarker testing results, current evidence, and patient-specific factors. Don’t miss the opportunity to visualize the underlying mechanisms of action of new and emerging agents through a unique whiteboard animation video!
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/accelerating-evidence-practice-new-treatment-advances-overcome-endocrine
- Start Date: 2024-10-04 05:00:00
- End Date: 2024-10-04 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.75 hours
AMA PRA Category 1 Credit™️: 0.75 hours
Nursing: 0.75 hours
Pharmacy: 0.75 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 40000.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all